New Zealand Markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
16.40+0.03 (+0.18%)
At close: 04:00PM EDT
16.11 -0.29 (-1.77%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close16.37
Bid16.21 x 3000
Ask0.00 x 21500
Day's range16.25 - 16.49
52-week range12.28 - 16.50
Avg. volume2,755,444
Market cap50.988B
Beta (5Y monthly)0.70
PE ratio (TTM)31.18
EPS (TTM)0.53
Earnings dateN/A
Forward dividend & yield0.66 (4.09%)
Ex-dividend date29 Sept 2022
1y target est17.99
  • Business Wire

    Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

    OSAKA, Japan & CAMBRIDGE, Mass., March 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90 and 100 in the 5mg, 15mg and

  • GlobeNewswire

    HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufac

  • Zacks

    Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.